CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV
101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven
autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24
participants who will receive 1 dose of KYV-101 and will be followed for 2 years.